Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

MERCK AND COMPANY : Ex-dividend day for

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/14/2018 CEST

A dividend is removed today from Merck and Company's share.



© Factset 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
06/18MERCK AND : Late-Breaking Data to be Presented from the Comparative Trials with ..
PU
06/18BRISTOL MYERS SQUIBB : BMS scores China's first IO approval
AQ
06/15MERCK AND : Modern Alchemists Are Making Chemistry Greener
AQ
06/15MERCK AND : `s Keytruda snags I-O`s first cervical cancer nod to back up HPV fig..
AQ
06/15MERCK AND : FDA Grants Priority Review to Merck's Supplemental Biologics License..
AQ
06/15MERCK AND : FDA Approves Merck's KEYTRUDA for Treatment of Refractory or Relapse..
AQ
06/14MERCK AND : FDA Approves Merck's KEYTRUDA for Previously Treated Patients with R..
AQ
06/14MERCK AND : rebuts petition urging SCOTUS to ignore Fosamax appeal
AQ
06/14MERCK AND COMPANY : Ex-dividend day for
FA
06/13MERCK AND : FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Treatment o..
BU
More news
News from SeekingAlpha
11:05aALZHEIMER'S DISEASE : A History Of Drug Failures 
06/173 THINGS IN BIOTECH, JUNE 16 : Do You Know Anything About EHA? 
06/16Dynavax Gives A Welcome Business Update 
06/163 THINGS IN BIOTECH, JUNE 15 : Keep Rolling, Pembro 
06/15Avoiding The 'Black Hole' Of Disease Development 
Financials ($)
Sales 2018 42 072 M
EBIT 2018 13 566 M
Net income 2018 7 224 M
Debt 2018 15 754 M
Yield 2018 3,20%
P/E ratio 2018 23,47
P/E ratio 2019 15,87
EV / Sales 2018 4,34x
EV / Sales 2019 4,14x
Capitalization 167 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 69,1 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY8.39%166 880
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 330
ROCHE HOLDING LTD.-14.81%184 168
AMGEN6.39%122 422